Predicine

March is Colorectal Cancer Awareness Month! 💙 At Predicine, we’re transforming colorectal cancer care with cutting-edge liquid biopsy and tissue-free MRD assays. Early screening saves lives, and Innovative liquid biopsy technology is redefining CRC detection, drug development, and personalized treatment. Better insights, better outcomes. This month, we encourage you to join us in raising awareness and empowering individuals with knowledge. Talk to your doctor about screening options and join us in the fight against colorectal cancer! #ColorectalCancerAwareness #EarlyDetectionSavesLives #PrecisionMedicine #Predicine 

Meet Predicine at the 9th Liquid Biopsy for Precision Oncology Summit! 📍 Feb 18-20, 2025 | San Diego, CA    Visit Predicine booth to explore how Predicine’s Accurate, Accessible, and Affordable (AAA) liquid biopsy solutions are accelerating biomarker discovery, global clinical trials, CDx development, and commercialization.    Key Highlights:  • Personalized MRD and Methylation-based MRD – Liquid, tissue, and tumor-agnostic approaches for minimal residual disease, recurrence, and molecular response.  • Comprehensive Genomic Profiling – Detecting SNVs, indels, fusions, and CNVs including amplification (HER2 & MET) and deletions (PTEN, BRCA, MTAP) for targeted therapy selection.  • PredicineCOMPLETE – Comprehensive molecular profiling integrating genomic, epigenomic, and transcriptomic insights to measure response, resistance, and expression.  • Globally Harmonized Solutions – Harmonized assays to support clinical trials and commercialization in the US, JP, EU China.    Let’s connect and discuss how we can drive precision oncology forward together! 📅 Schedule a meeting: https://lnkd.in/gxVYKhR5    #lbxsandiego #LiquidBiopsy #PrecisionOncology #MRD #CompanionDiagnostics #CancerResearch #Methylation #RNAExpression #Deletion #China 

On Day 2 of ASCO-GU, Predicine proudly announce three urine-based ctDNA studies in urothelial carcinoma (UC):   Today’s Highlights:  • ctDNA genomic profiling using PredicineCARE™, improving clinical staging for upper tract urothelial carcinoma (UTUC). <oral presentation by @ Roger Li from Moffitt>  • Methylation tumor fraction study using PredicineEPIC™, enabling early detection and recurrence monitoring of UC, with an AUC of 0.96. <poster H8 by Dr. Huan Zhao from CICAMS>  • utDNA fragmentomic study using PredicineSCORE™ for improved UC diagnosis. <poster H10 by Dr. Huan Zhao from CICAMS >  • Comprehensive molecular profiling using PredicineCOMPLETE™, integrating genomic, epigenomic, and transcriptomic profiling. (poster H24 by @Alan Tan from Vanderbilt>    Stop by Predicine Booth #56 or schedule a meeting https://lnkd.in/gZKYGK26 to explore Predicine’s liquid biopsy solutions in clinical trial and patient testing.    #ASCOGU2025 #Predicine #LiquidBiopsy #UC #PrecisionOncology #CancerResearch #ClinicalTrials #CDx 

Stop by Predicine Booth #56 on Day 1 of ASCO-GU and explore our latest publications on liquid biopsy in mCRPC.    Discover the power of Predicine’s cutting-edge liquid biopsy solutions in metastatic castration-resistant prostate cancer (mCRPC).    Highlights:  • 43% of mCRPC patients received on-label treatment recommendations through comprehensive testing.  • PredicineCARE™ cfDNA alone identified 68% of actionable cases, reducing reliance on tissue biopsies.  • Repeat cfDNA testing uncovered 28% more patients with treatment recommendations.    Visit Booth #56 or Schedule a meeting: https://lnkd.in/gZKYGK26   to explore how our global network of labs and decentralized CDx and kit manufacturing is advancing clinical trials, biomarker discovery, and CDx development worldwide.    #ASCOGU2025 #Predicine #LiquidBiopsy #mCRPC #PrecisionOncology #CancerResearch #ClinicalTrials #CDx

Predicine Liquid Biopsy Summit 2025 - Shanghai     We're excited for the upcoming Predicine Liquid Biopsy Summit 2025 - Shanghai on February 9, 2025. 👏 Join us for an insightful event featuring industry and clinical experts in liquid biopsy and precision oncology.  Event Highlights:  • Baseline-informed personalized MRD vs. tumor-agnostic MRD   • Blood and urine-based ctDNA studies for treatment selection, monitoring, and resistance MOA  • Predicine’s globally harmonized liquid biopsy solutions for clinical trials, CDx development, and commercialization    Don’t miss this opportunity to network, partner and learn. Register here: https://lnkd.in/gzfwxbzR     We look forward to seeing you in Shanghai! 

We’re looking forward to ASCO GU 2025 in San Francisco and hope to see you there.    Don’t miss 5 studies utilizing Predicine’s blood- and urine-based liquid biopsy solutions for treatment selection, MRD, and comprehensive molecular profiling integrating genomics, epigenomics and transcriptomics.     Meet with Predicine at Predicine Booth #56 and register for the Annual Predicine ASCO GU Networking Reception on Thursday evening February 13th. Register HERE: https://lnkd.in/gwR54hSX   Schedule a meeting: Connect with our experts to discuss collaboration opportunities in clinical trials, CDx and commercialization: Schedule Here: https://lnkd.in/gZKYGK26   Let’s drive innovation in GU oncology together!     #ASCOGU25 #LiquidBiopsy #PrecisionOncology #ClinicalTrials #CDx

🌍🎗️ Today is World Cancer Day 🎗️🌍  At Predicine, we stand united in the fight against cancer, advancing precision medicine to empower patients and healthcare providers with next-generation liquid biopsy technology. Predicine's Accurate, Accessible and Affordable (AAA) liquid biopsy solutions are revolutionizing precision oncology. With a global network of centralized labs and decentralized kitted solutions, we’re advancing clinical trials, biomarker discovery, and CDx development across the US, EU, China, and beyond. Every breakthrough, every test, and every discovery bring us closer to a future where cancer is detected earlier, treated more effectively, and ultimately defeated. Join us in raising awareness and supporting those impacted by cancer. 💜 #Predicine #PrecisionMedicine #WorldCancerDay   

Visit Predicine on Day 3 of ASCO-GI 2025 and explore our GI Disease Area Strategy (DAS) and ctDNA MRD publications in colorectal cancer (CRC).    Highlights:  • NEJM: Tissue-free, blood-informed PredicineBEACON™ personalized MRD for clinical trials, the New England Journal of Medicine 2023.  • Nat Med: Therapy monitoring and resistance mutation tracking with blood-informed PredicineBEACON™ for Combination Therapy, Nature Medicine 2023.  • Clin Cancer Res: Tumor fraction (TF) monitoring with PredicineBEACON™ for treatment response tracking, Clinical Cancer Research 2024.    Visit Predicine booth #24 or schedule a meeting: https://lnkd.in/g6BKHJm6    #ASCOGI2025 #MRD #KRASG12C #ctDNA #LiquidBiopsy #PrecisionOncology #Predicine #CancerResearch #ClinicalTrials #CRC 

Meet Predicine team on Day 2 of ASCO-GI 2025 and explore Predicine’s Disease Area Strategy (DAS) in GI and learn about our latest publications on ctDNA clinical applications - from comprehensive genomic profiling to MRD.    Highlights:  HCC: tissue-informed PredicineBEACON™ personalized MRD assay in perioperative hepatocellular carcinoma (HCC), Clinical Cancer Research 2024. https://lnkd.in/get_mEYQ CCA: 152-gene PredicineCARE™ for comprehensive genomic profiling in cholangiocarcinoma (CCA) etc., Nature Medicine 2024. Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial | Nature Medicine PDAC: 600-gene PredicineATLAS™ for resistance mechanisms in mPDAC, Nature Communications 2022. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma | Nature Communications BTC: 600-gene PredicineATLAS™ for Therapy Monitoring in biliary tract cancer (BTC) trials, Lancet Gastroenterology & Hepatology 2022. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study - The Lancet Gastroenterology & Hepatology   Visit Predicine booth #24 or schedule a meeting : https://lnkd.in/g6BKHJm6   #ASCOGI2025 #HCC #CCA #BTC #PDAC #PrecisionOncology #LiquidBiopsy #MRD #CancerResearch #ClinicalTrials #Predicine 

Meet Predicine team on Day 1 of ASCO-GI 2025 and explore Predicine’s Disease Area Strategy (DAS) in gastric cancer and Nature Communications publication on ctDNA clinical application - from comprehensive genomic profiling to MRD. Highlights: • Blood informed vs tumor agnostic methylation MRD • HER2 amplification accurately detected in plasma by 152-gene PredicineCARE™ • Treatment Prediction with PredicineSCORE™ whole genome sequencing • Monitoring resistance mutations with ultra-highly sensitive PredicineCARE™ ULTRA Welcome to Booth #24 to explore how our global network of labs and decentralized CDx and kit manufacturing is advancing clinical trials, biomarker discovery, and CDx development worldwide. #ASCOGI2025 #PrecisionOncology #LiquidBiopsy #GastricCancer #MRD #CancerResearch